New EPO Study: Patents And Innovation Against Cancer

MC
Marks & Clerk

Contributor

Marks & Clerk is one of the UK’s foremost firms of Patent and Trade Mark Attorneys. Our attorneys and solicitors are wired directly into the UK’s leading business and innovation economies. Alongside this we have offices in 9 international locations covering the EU, Canada and Asia, meaning we offer clients the best possible service locally, nationally and internationally.
The EPO has recently released a study with interesting insights on the recent trends in protecting cancer technologies worldwide. The study has found that the number of international...
UK Technology
To print this article, all you need is to be registered or login on Mondaq.com.

The EPO has recently released a study with interesting insights on the recent trends in protecting cancer technologies worldwide. The study has found that the number of international patent families relating to the fight against cancer has surged by 70% between 2015 and 2021, and this has been attributed to the surge in new technologies such as immunotherapy, gene therapy, and AI. Read more below!

New study shows inventions to fight cancer are up by more than 70% since 2015

www.epo.org/...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

New EPO Study: Patents And Innovation Against Cancer

UK Technology

Contributor

Marks & Clerk is one of the UK’s foremost firms of Patent and Trade Mark Attorneys. Our attorneys and solicitors are wired directly into the UK’s leading business and innovation economies. Alongside this we have offices in 9 international locations covering the EU, Canada and Asia, meaning we offer clients the best possible service locally, nationally and internationally.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More